Instrument Inactif

Communiqués F-star Therapeutics, Inc.

Actions

FSTX

US30315R1077

Recherche biotechnologique et médicale

Communiqués

09/03/23	F star Therapeutics : Acquisition/Asset Disposal - Form 8-K	PU
09/03/23	F-STAR THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
09/03/23	InvoX Pharma Completes Acquisition of F-star Therapeutics, Inc.	BU
07/03/23	F-STAR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
07/03/23	F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma	AQ
07/03/23	F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma	GL
06/03/23	F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23/02/23	F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
09/02/23	F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
01/02/23	F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
26/01/23	InvoX Pharma and F-star Therapeutics issue Joint Statement	GL
26/01/23	InvoX Pharma and F-star Therapeutics issue Joint Statement	GL
30/12/22	F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
29/12/22	F star Therapeutics : Other Event - Form 8-K	PU
29/12/22	F-STAR THERAPEUTICS, INC. : Other Events (form 8-K)	AQ
21/12/22	F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19/12/22	F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/12/22	F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress	GL
06/12/22	F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress	AQ
21/11/22	F-STAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/11/22	F-STAR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
07/11/22	F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research	GL
07/11/22	F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research	AQ
01/11/22	F-STAR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
11/08/22	F star Therapeutics : Reports Second Quarter 2022 Financial Results and Corporate Highlights - Form 8-K	PU